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Introduction: Cryptococcal infections pose a diagnostic challenge in an immunocompetent host. Asbestos
exposure has been associated with pulmonary aspergillosis. This case highlights an interesting presentation of
cryptococcal lung inflammation with underlying asbestosis.
Case presentation: A 63-year-old Mediterranean Caucasian woman presented with progressive dry cough of nine
months duration. A computed tomography (CT) scan of her chest revealed multiple foci in the right infra-hilar
region, which were seen as hot lung masses on a positron emission tomography (PET) scan. These multiple foci
appeared metastatic in nature throughout both lung fields with early mediastinal invasion. A computed
tomography (CT)-guided core biopsy was obtained from a dominant right lower lobe lung mass. Histology showed
chronic granulomatous inflammation with numerous budding yeast forms that were GMS-, PAS-, and mucin-
positive, consistent with cryptococcosis together with asbestos bodies (ferruginous). She was managed with
fluconazole (400mg (6mg/kg) per day orally) daily. At her six-month follow up, she had marked improvement in her
general condition along with a diminution of the lower lobe lung mass.
Conclusion: We report a clinical and radiological improvement in a patient treated for cryptococcal pneumonia.
Asbestos exposure was likely to have been an important pathophysiological precursor to infection by
environmental fungi.
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The pathogenic role of asbestos exposure prior to the de-
velopment of pulmonary cryptococcal infections is not
well defined. A few clinical reports [1-3] have linked as-
bestos exposure and pulmonary aspergillosis. None of the
case reports with prior exposure to asbestos have been
linked to pulmonary cryptoccocal infection. Diseases
related to Cryptococcus neoformans or C. gattii have be-
come increasingly prevalent in immunocompromised
patients (including those with AIDS, prolonged treatment
with glucocorticoids, organ transplantation or malignancy).
There are descriptions of pulmonary cryptococcosis in* Correspondence: razashahzad2@gmail.com
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reproduction in any medium, provided the orapparently immunocompetent patients [4,5]. Typically, in-
fection first occurs when the patient inhales the basidios-
pore form of the fungus. A small focal pneumonitis
develops that may or may not be symptomatic. Since
certain cryptococcal strains may be more virulent than
others, the systemic inflammatory response varies from
one patient to another. Cryptococci have a tropism for
the central nervous system (CNS); after the CNS, the
respiratory system is most commonly affected. The clin-
ical manifestations of pulmonary cryptococcosis include
localized nodular lesions, with or without cavitation, seg-
mental pneumonic infiltrates, patchy interstitial or al-
veolar infiltrates, pleural effusions, hilar masses and
thoracic lymphadenopathy. This case highlights an inter-
esting presentation of cryptococcal lung inflammation
with underlying asbestosis.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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A 63-year-old Mediterranean Caucasian woman presented
with mild dyspnea on exertion and a progressive worsening
of a dry cough of nine months’ duration. Born in Turkey,
she had a history of exposure to asbestos via building mate-
rials commonly used in eastern Turkey. She immigrated to
the United States at the age of 37. Shortly after arrival in
New York she was diagnosed with and treated for pulmon-
ary tuberculosis. (The diagnosis and treatment records were
confirmed by the New York City Department of Health.)
She had no fever, night sweats, hemoptysis or weight loss.
She had no history of allergies; she had never smoked or
used illicit drugs. Other than her birth in Turkey and immi-
gration to the US she had no other travel history.
Initial examination included a chest X-ray, which
showed fibrocalcific changes at the upper lung fields bi-
laterally as well as a right lower lobe mass density. A
computed tomography (CT) scan of the chest revealed
multifocal pleural scarring, appearing metastatic in na-
ture, throughout both lung fields with early mediastinal
invasion in the right infrahilar region (Figure 1). Positron
emission tomography (PET) scan revealed FDG (fluoro-
deoxyglucose (18 F))-PET positive multiple lung masses.
A computed tomography (CT)-guided core biopsy of a
dominant right lower lobe lung mass was obtained. The
histopathological specimen findings included chronic
granulomatous inflammation (multi-nucleated cells with
central necrosis) with numerous budding yeast forms
that were positive for Grocott's methenamine silver stainFigure 1 A. Chest X-ray shows fibrocalcific changes, right lower lobe
scarring in multiple foci, throughout both lung fields with early mediastina
month shows diminished right lower lobe opacity.(GMS), Periodic acid-Schiff (PAS) and mucin stain, con-
sistent with cryptococcosis. Ferruginous bodies were also
present, consistent with asbestos bodies (Figure 2). Cul-
tures of the specimen examined for acid fast bacilli and
fungi were negative, as were bacterial cultures. Serum
cryptococcal antigen and HIV enzyme-linked immuno-
sorbent assay (ELISA) were negative. A summary of the
significant clinical data is illustrated in the table.
She was treated with fluconazole (400mg (6mg/kg) per
day orally) for four months. She reported a marked im-
provement in her symptoms and improvement in her
general condition. At her four-month follow up, a chest
radiograph showed a significant reduction of the basilar
infiltrates bilaterally.
Discussion
Disease related to C. neoformans or C. gattii has become
increasingly prevalent in immunocompromised patients
(including those with AIDS, prolonged treatment with
glucocorticoids, organ transplantation or malignancy).
There are descriptions of pulmonary cryptococcosis in
apparently immunocompetent patients [4,5]. Typically,
infection first occurs when the patient inhales the basi-
diospore form of the fungus. A small focal pneumonitis
develops that may or may not be symptomatic. Since
certain cryptococcal strains may be more virulent than
others, the systemic inflammatory response varies from
one patient to another. Cryptococci have a tropism for
the CNS; after the CNS, the respiratory system is mostmass. B and C: Chest computed tomography (CT) scan shows pleural
l invasion. Right lower lobe mass (biopsy site). Chest X-ray at four
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monary cryptococcosis include localized nodular lesions,
with or without cavitations, segmental pneumonic infil-
trates, patchy interstitial or alveolar infiltrates, pleural
effusions, hilar masses, and thoracic lymphadenopathy.
In our case, the patient had progressive localized disease
without any systemic inflammatory response; the initial
presentation was indolent. Her radiograph showed
nodules and masses. These findings, compatible with a
chronic infection of low virulence, simulated the presen-
tation of a malignant lung disease.
Patients who are symptomatic with cryptococcal pneu-
monia can present with cough, chest pain, increased
sputum production, fever, weight loss and hemoptysis.
Campbell AU et al. reported 32% of the patients with
pulmonary cryptococcosis to be asymptomatic; in these
cases pulmonary infection was discovered as an inciden-
tal finding [4].
Asymptomatic patients with chest radiographic find-
ings suspicious for malignancy who undergo biopsy are
occasionally found to have cryptococcosis. Global eco-
logical studies have found C. neoformans in soil samples
from around the world in areas frequented by birds, es-
pecially pigeons and chickens. More than 50 tree species
have yielded C. gattii especially from decayed hollows,
suggesting a possible ecological niche [6].
Eastern Turkey is a region in which asbestos was
mined and used in building materials. There are many
caves which are a habitat for pigeons and, most likely,
cryptococci. This environment was likely a source ofFigure 2 Cryptococci surrounded by a clear capsule (black arrows) ar
with multinucleated giant cells present in the left upper quadrant. (A
PAS stain. Budding forms are evident. (C) The GMS stain demonstrates yeas
budding, typical features of Cryptococcus. (D) The outer wall of the fungi s
arrows) are surrounded by a clear capsule. A positive mucicarcmine stain c
bodies.both her asbestos exposure and, perhaps, also her expos-
ure to cryptococci (although New York City is also an
endemic area for pigeons and cryptococci.).
In determining whether particular environmental, med-
ical, or behavioral risk factors existed among C. gattii,
MacDougall L et al. found the following risk factors:
age ≥50, current smokers, HIV infection, and invasive
cancer [7].
Hammar SP et al. [8] have shown that asbestos may
cause localized lesions in the lung that clinically and
radiographically are misinterpreted as cancer. Patho-
logical examination of nodules from the lung tissue of
patients with prior exposure to asbestos showed intra-
luminal fibrosis and inflammation of the distal airways, a
pattern of change frequently referred to as ‘bronchiolitis
obliterans organizing pneumonitis’ (BOOP). That asbes-
tos can potentially produce a localized BOOP-like pul-
monary lesion in humans was first suggested in a case
report from 1961 [9]. Asbestos bodies were present in
association with proinflammatory tissue including alveo-
lar macrophages, occasionally containing asbestos bodies
within the cytoplasm.
Hillerdal and Heckscher [2] reported aspergillus infec-
tion in four persons with asbestos-related lung changes.
They found that degenerative changes of the bronchi
can occur in asbestotic lungs and lead to both cylindrical
bronchiectasis and fibrotic narrowing. Additional
asbestos-induced bronchial changes include ‘broom de-
formation’, in which asbestos pleurisy leaves considerably
thickened and fibrotic pleura. The bronchi beneath suche present in a background of non-specific chronic inflammation
) Hematoxylin and eosin stain. (B) The fungi are clearly seen with a
t forms with marked size variation and budding and narrow-based
tain positive with the mucicarmine stain and the organisms (black
onfirms the diagnosis of cryptococcosis. (E) Multiple ferruginous
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shrinkage of the pleural fibrotic tissue [9-11]. These
bronchial changes increase the risk for secondary infec-
tion, including, but not limited to, fungal growth. Fungal
superinfection might also be due to the malfunction of
immunological surveillance among patients exposed to
asbestos. This complex effect was detailed by Miller
[12]. Macrophages are activated, and among other
things, attract various populations of lymphocytes, an
increased level of autoantibodies in the blood, as well as
overall increased levels of immunoglobulin G (IgG), IgA,
and IgM. Recent in vitro studies have demonstrated that
asbestos acts on peripheral T cells as a super-antigen,
causing a depressed function of T-lymphocytes, which
might be the reason for the increase in autoantibodies
[2]. The hypothesis of malfunction of immunological
surveillance is supported by the high incidence of malig-
nancies among patients exposed to asbestos [13].
The hypothesis that pulmonary tuberculosis might be
the predisposing factor for pulmonary cryptococcosis in
our patient is less likely in the absence of active disease.
Segal [14] has found that silica-impaired macrophages are
incapable of targeting inhaled conidia, impairing the cellu-
lar defense to this microbiological challenge, predisposing
the patient with silicosis to increased risk for pulmonary
mycosis. Coal mine dust and asbestos fibers are probably
less toxic to macrophages than crystalline silica. Therefore,
those affected with silicosis are more commonly affected
by autoimmune diseases and systemic immunologic com-
plications [1]. Future studies should focus on the associ-
ation of cryptococcal infection with exposure to asbestos
and silica dust.
We initially employed the usual diagnostic tools for pul-
monary cryptococcosis which include histology, fungal
culture, serum cryptococcal antigen, and radiography.
However, if the results are inconclusive, biopsy is recom-
mended. The yeast form of cryptococci can be identified
in histopathological specimens using the GMS stain. In
our case, budding yeast were identified. Vacuoles in tissue
were also seen, likely representing lipid or fat. The muci-
carmine stain shows both the yeast form and the capsule
and the Fontana-Masson stain reveals melanin contained
in the yeast. The identification of C. neoformans is sup-
ported by the presence of a urease-positive, encapsulated
yeast. Further confirmation can be achieved with bio-
chemical tests contained in commercial kits and by detec-
tion of the enzyme phenol oxidase, which is solely
produced by C. neoformans. However, most clinical micro-
biology laboratories do not stock the expensive agars
required for detecting this enzyme. Most laboratories use
a variety of sugar fermentations contained in commercial
kits to identify the organism.
Fluconazole is active against C. neoformans, is eas-
ily administered, and has an excellent safety profile.Candidates for treatment clearly include patients with
persistent and/or disabling symptoms, those with mul-
tiple nodules or extensive infiltrates on chest x-ray, and/
or those with positive serum cryptococcal antigen test
results.
Additional studies will be needed to determine more
precisely the role of fluconazole in the treatment of
Isolated pulmonary crptococcosis IPC in immunocom-
petent patients as well as the optimal dosage and dur-
ation of therapy [15]. Similarly, the optimal fluconazole
dosage has not been well defined. Dromer et al. [16] and
Yamaguchi et al. [17] both employed a daily fluconazole
dose of 200 to 400mg, whereas Yew et al. [18] utilized
an ‘induction’ dose of 600mg for four weeks, followed
by 400mg for 10 to 12 weeks. In our case, the patient
was treated with fluconazole (400mg (6mg/kg) per day
orally). At her four-month follow up, there was marked
improvement in her general condition along with dim-
inution of the lower lobe lung mass on her repeat chest
X-ray.Conclusions
We report an interesting case of cryptococcal pneumo-
nia with successful clinical and radiological improve-
ment with fluconazole. In view of her history of
asbestos exposure, antecedent treatment for tubercu-
losis, lack of systemic inflammatory response and a
radiologic appearance of a mass lesion, malignancy was
suspected. Biopsy was essential to exclude malignancy.
The histological findings of ferruginous bodies confirmed
the radiographic appearance of asbestosis. In this case,
asbestos exposure was likely to have been an important
pathophysiological precursor both to the patient’s
tuberculosis and to her susceptibility to infection by envir-
onmental fungi.Consent
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